CareDx shares have doubled in 2026. Will July 30 earnings support the surge?
CareDx reports Q2 results on July 30 as investors assess transplant testing growth, Medicare coverage clarity and the Naveris strategy.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.